
    
      A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics
      and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing
      Schedules in Patients with Advanced Solid Malignancies.
    
  